Canaccord Genuity Maintains Buy on Helus Pharma, Lowers Price Target to $42
Canaccord Genuity analyst Sumant Kulkarni maintains Helus Pharma (NASDAQ: HELP ) with a Buy and lowers the price target from $45 to $42.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.